Marsela Braunstein
Director, Radioconjugates AstraZeneca
Seminars
Thursday 23rd July 2026
Enhancing Radioligand Therapy Efficacy through Rational Combination with DDR Inhibitors
1:30 pm
- Exploring DNA damage synergy between alpha/beta emitters and DDR inhibitors to amplify tumor cell killing
- Optimizing preclinical combination timing and sequencing to maximize efficacy while minimizing toxicity
- Identifying biomarkers to guide patient selection and predict responsiveness in combination strategies
